{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Non-Small+Cell+Carcinoma&page=28",
    "query": {
      "condition": "Lung Non-Small Cell Carcinoma",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 3653,
    "total_pages": 366,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Non-Small+Cell+Carcinoma&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Non-Small+Cell+Carcinoma&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T04:57:19.025Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07323732",
      "title": "A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC",
        "NSCLC, Stage I",
        "NSCLC Stage II",
        "Non Small Cell Lung Cancer",
        "Non-small Cell Lung Cancer Stage I",
        "Non-small Cell Lung Cancer Stage II",
        "Interstitial Lung Disease",
        "Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)"
      ],
      "interventions": [
        {
          "name": "BIO 300",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2026-01-06",
      "completion_date": "2029-01-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-16T04:57:19.025Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "East White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07323732"
    },
    {
      "nct_id": "NCT00423436",
      "title": "Interactive Voice Response (IVR) Symptom Assessment in Non-Small Cell Lung Cancer (NSCLC) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Interactive Voice Response Telephone System",
          "type": "BEHAVIORAL"
        },
        {
          "name": "IVR Plus Triage",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2003-04",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2011-12-16",
      "last_synced_at": "2026-10-16T04:57:19.025Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423436"
    },
    {
      "nct_id": "NCT00283244",
      "title": "Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "70 Years to 120 Years"
      },
      "enrollment_count": 147,
      "start_date": "2006-03",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2017-04-24",
      "last_synced_at": "2026-10-16T04:57:19.025Z",
      "location_count": 11,
      "location_summary": "Fayetteville, Arkansas • Savannah, Georgia • Evanston, Illinois + 8 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00283244"
    },
    {
      "nct_id": "NCT03628144",
      "title": "Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "NSCLC",
        "Non-small Cell Lung Cancer",
        "Non-small Cell Lung Cancer Stage IIIB",
        "Non-small Cell Lung Cancer Stage ⅢA",
        "NSCLC Stage IIIB",
        "NSCLC, Stage IIIA"
      ],
      "interventions": [
        {
          "name": "Impact® Advanced Recovery",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Boost® High Protein",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Quality of life (EORTC-QLQ-30)",
          "type": "OTHER"
        },
        {
          "name": "Evaluation of Cognitive Function (FACT-Cog, v. 3.0)",
          "type": "OTHER"
        },
        {
          "name": "Mindfulness Questionnaire (FFMQ)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "RADIATION",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-07",
      "completion_date": "2023-09",
      "has_results": false,
      "last_update_posted_date": "2020-09-10",
      "last_synced_at": "2026-10-16T04:57:19.025Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03628144"
    },
    {
      "nct_id": "NCT05704634",
      "title": "A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Kevzara (Sarilumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2023-08-18",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-16T04:57:19.025Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05704634"
    },
    {
      "nct_id": "NCT04210492",
      "title": "Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "45 Gray (Gy) regimen",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2020-08-26",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-16T04:57:19.025Z",
      "location_count": 6,
      "location_summary": "Greenwich, Connecticut • Guilford, Connecticut • Hamden, Connecticut + 3 more",
      "locations": [
        {
          "city": "Greenwich",
          "state": "Connecticut"
        },
        {
          "city": "Guilford",
          "state": "Connecticut"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Trumbull",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04210492"
    },
    {
      "nct_id": "NCT04189614",
      "title": "An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Cofetuzumab Pelidotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2020-02-13",
      "completion_date": "2026-05-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-16T04:57:19.025Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Springdale, Arkansas • Stanford, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04189614"
    },
    {
      "nct_id": "NCT04306900",
      "title": "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "TTX-030, budigalimab and mFOLFOX6",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, budigalimab and docetaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030 and mFOLFOX6",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030 and budigalimab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, budigalimab, nab-paclitaxel and gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030 and pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, nab-paclitaxel and gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Budigalimab and mFOLFOX6",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Trishula Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 185,
      "start_date": "2020-03-30",
      "completion_date": "2024-03-27",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-10-16T04:57:19.025Z",
      "location_count": 26,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04306900"
    },
    {
      "nct_id": "NCT00326599",
      "title": "Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cediranib maleate",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2007-06",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2017-03-21",
      "last_synced_at": "2026-10-16T04:57:19.025Z",
      "location_count": 154,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 95 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Aurora",
          "state": "Illinois"
        },
        {
          "city": "Bloomington",
          "state": "Illinois"
        },
        {
          "city": "Canton",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00326599"
    },
    {
      "nct_id": "NCT02637531",
      "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors (Part A/B/C/D)",
        "Non-small Cell Lung Cancer (Part E)",
        "Melanoma (Part E)",
        "Squamous Cell Cancer of the Head and Neck (Part E)",
        "Triple Negative Breast Cancer (Part F)",
        "Adrenocortical Carcinoma (Part G)",
        "Mesothelioma (Part G)",
        "High-circulating Myeloid-derived Suppressor Cells (Part H)"
      ],
      "interventions": [
        {
          "name": "IPI-549 (eganelisib)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Infinity Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2015-12",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-10-16T04:57:19.025Z",
      "location_count": 11,
      "location_summary": "San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02637531"
    }
  ]
}